

**UNITED STATES DEPARTMENT OF COMMERCE****Patent and Trademark Office**

Address: COMMISSIONER OF PATENTS AND TRADEMARKS  
Washington, D.C. 20231

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.
-----------------	-------------	----------------------	---------------------

09/661,693 09/14/00 PATHER

5 CIMA 3.0-030

000530  
LERNER, DAVID, LITTENBERG,  
KRUMLHOLZ & MENTLIK  
600 SOUTH AVENUE WEST  
WESTFIELD NJ 07090

HM22/0925

EXAMINER

DEWITTY, R

ART UNIT	PAPER NUMBER
----------	--------------

1616

DATE MAILED:

09/25/01 6

**Please find below and/or attached an Office communication concerning this application or proceeding.**

**Commissioner of Patents and Trademarks**

<b>Office Action Summary</b>	Application No.	Applicant(s)	
	09/327,814	PATHER ET AL.	
	Examiner	Art Unit	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

**Period for Reply**

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).
- Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

**Status**

- 1) Responsive to communication(s) filed on 21 May 2001.
- 2a) This action is FINAL.                            2b) This action is non-final.
- 3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

**Disposition of Claims**

- 4) Claim(s) 14-21 is/are pending in the application.
- 4a) Of the above claim(s) \_\_\_\_\_ is/are withdrawn from consideration.
- 5) Claim(s) \_\_\_\_\_ is/are allowed.
- 6) Claim(s) 14-21 is/are rejected.
- 7) Claim(s) \_\_\_\_\_ is/are objected to.
- 8) Claim(s) \_\_\_\_\_ are subject to restriction and/or election requirement.

**Application Papers**

- 9) The specification is objected to by the Examiner.
- 10) The drawing(s) filed on \_\_\_\_\_ is/are: a) accepted or b) objected to by the Examiner.
- Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
- 11) The proposed drawing correction filed on \_\_\_\_\_ is: a) approved b) disapproved by the Examiner.
- If approved, corrected drawings are required in reply to this Office action.
- 12) The oath or declaration is objected to by the Examiner.

**Priority under 35 U.S.C. §§ 119 and 120**

- 13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) All    b) Some \* c) None of:
1. Certified copies of the priority documents have been received.
2. Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.
3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).
- \* See the attached detailed Office action for a list of the certified copies not received.
- 14) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).
- a) The translation of the foreign language provisional application has been received.
- 15) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.

**Attachment(s)**

- 1) Notice of References Cited (PTO-892)                            4) Interview Summary (PTO-413) Paper No(s). \_\_\_\_\_ .
- 2) Notice of Draftsperson's Patent Drawing Review (PTO-948)                    5) Notice of Informal Patent Application (PTO-152)
- 3) Information Disclosure Statement(s) (PTO-1449) Paper No(s) \_\_\_\_\_ .                    6) Other: \_\_\_\_\_

## DETAILED ACTION

Claims 14-21 are pending in the instant application.

### ***Claim Rejections - 35 USC § 102***

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless –

(e) the invention was described in a patent granted on an application for patent by another filed in the United States before the invention thereof by the applicant for patent, or on an international application by another who has fulfilled the requirements of paragraphs (1), (2), and (4) of section 371(c) of this title before the invention thereof by the applicant for patent.

1. Claims 14-15, 17-21 are rejected under 35 U.S.C. 102(b) as being anticipated by DiSanto (U.S. Pat. No. 6,117,912).

DiSanto relates to the administration of selegiline buccally or sublingually.

Selegiline responsive diseases include neuronal-degenerative diseases, depression, and ADHD.

At example 3, column 6, DiSanto teaches an effervescent selegiline tablet for sublingual or buccal administration.

### ***Claim Rejections - 35 USC § 103***

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

2. Claims 14-21 are rejected under 35 U.S.C. 103(a) as being unpatentable over DiSanto, further in view of Tsuk et al. (U.S. Pat. No. 3,972,995).

As stated above, DiSanto teaches an effervescent tablet useful for neuronal-degenerative diseases, depression and ADHD, that is applied sublingually or buccally. However, DiSanto does not teach the incorporation of a bioadhesive.

Tsuk et al. relates to dosages forms for buccal administration of a drug. The dosage form of Tsuk et al. contains a moisture-activated adhesive precursor. In use, the dosage form is applied to the inside of the oral cavity, such that the drug is exposed to a small area of the oral mucosa while isolating the drug from the remainder of the oral cavity (col. 1, line 65-col. 2, line 7). By isolating the drug from the remainder of the oral environment, high drug blood levels are rapidly achieved and maintained (col. 2, lines 40-48).

Based on the art available at the time the invention was made, one with ordinary skill in the art would have known of an effervescent tablet containing a medicament for sublingual or buccal administration and bioadhesive. Motivation to utilize a bioadhesive within such effervescent tablet would have arisen out of desire to obtain rapid high drug blood levels.

3. The prior art made of record and not relied upon is considered pertinent to applicant's disclosure. Eichman "Mechanistic Studies on Effervescent-Induced Permeability Enhancement" relates to the use of effervescent tablets for therapeutic treatment. Eichman teaches that numerous pharmaceutical products are being

marketed that contain effervescent preparations including, for example, antibiotics, antiacids, analgesics, and laxatives (page 48, first paragraph).


Callingham (U.S. Pat. No. 5028411) relates to pharmaceutical compositions for buccal administration. It is taught that buccal administration of the compositions may be carried out by effervescent tablets (col. 6, lines 50-64 (esp. line 63).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Robert M. DeWitty whose telephone number is 703-308-2411. The examiner can normally be reached on 9:00am - 5:00pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Jose Dees can be reached on 703-308-4527. The fax phone numbers for the organization where this application or proceeding is assigned are 703-308-7924 for regular communications and 703-308-7924 for After Final communications.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is 703-308-1235.

RMD  
September 13, 2001

  
JOSE G. DEES  
SUPERVISORY PATENT EXAMINER

1616